An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

Published:2013-12 Issue:12 Volume:8 Page:1529-1537
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Scagliotti Giorgio V.,Felip Enriqueta,Besse Benjamin,von Pawel Joachim,Mellemgaard Anders,Reck Martin,Bosquee Lionel,Chouaid Christos,Lianes-Barragán Pilar,Paul Elaine M.,Ruiz-Soto Rodrigo,Sigal Entisar,Ottesen Lone H.,LeChevalier Thierry

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis;Delbaldo;JAMA,2004

2. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003;Pfister;J Clin Oncol,2004

3. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients;Le Chevalier;J Clin Oncol,1994

4. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer;Einhorn;J Clin Oncol,1986

5. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial;Georgoulias;Lancet,2001

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer;Journal of Cancer Research and Clinical Oncology;2021-08-06

2. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians;Critical Reviews in Oncology/Hematology;2021-01

3. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non–small-cell lung cancer;Medicine;2019-06

4. Development of Ultrasound-Triggered and Magnetic-Targeted Nanobubble System for Dual-Drug Delivery;Journal of Pharmaceutical Sciences;2019-03

5. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review;Journal of Cancer;2019